TG Therapeutics Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 399

Employees

  • Stock Symbol
  • TGTX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $63.34
  • (As of Friday Closing)

TG Therapeutics General Information

Description

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 3020 Carrington Mill Boulevard
  • Suite 475
  • Morrisville, NC 27560-5435
  • United States
+1 (877)
Primary Industry
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 3020 Carrington Mill Boulevard
  • Suite 475
  • Morrisville, NC 27560-5435
  • United States
+1 (877)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TG Therapeutics Stock Performance

As of 20-Nov-2026, TG Therapeutics’s stock price is $63.34. Its current market cap is $9.6B with 151M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$63.34 $64.85 $26.76 - $68.03 $9.6B 151M 1.92M $0.74

TG Therapeutics Financials Summary

As of 30-Sep-2026, TG Therapeutics has a trailing 12-month revenue of $898M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 8,740,385 4,854,753 4,598,294 2,466,834
Revenue 897,763 616,287 329,004 233,662
EBITDA 196,504 134,361 49,902 26,100
Net Income 106,058 447,179 23,383 12,672
Total Assets 1,592,252 1,063,253 577,690 329,587
Total Debt 754,373 253,710 253,719 110,795
Public Fundamental Data provided by Morningstar, Inc. disclaimer

TG Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TG Therapeutics‘s full profile, request access.

Request a free trial

TG Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and
Pharmaceuticals
Morrisville, NC
399 As of 2026

Vienna, Austria
 

Karachi, Pakistan
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TG Therapeutics Competitors (17)

One of TG Therapeutics’s 17 competitors is Pfizer (Vienna), a Corporation company based in Vienna, Austria.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfizer (Vienna) Corporation Vienna, Austria
Pfizer Pakistan Corporation Karachi, Pakistan
Aytu Biopharma Formerly VC-backed Denver, CO
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 17 competitors. Get the full list »

TG Therapeutics Patents

TG Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026165590-A1 Subcutaneous formulations of therapeutic agents Pending 03-Feb-2025
AU-2025241863-A1 Subcutaneous formulations of anti-cd20 antibody Pending 18-Mar-2024
WO-2025199155-A1 Subcutaneous formulations of anti-cd20 antibody Pending 18-Mar-2024
AU-2023281714-A1 Anti-cd20 antibody compositions Pending 01-Jun-2022
EP-4286010-A1 Anti-cd20 antibody compositions Pending 01-Jun-2022 C07K16/2887
To view TG Therapeutics’s complete patent history, request access »

TG Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TG Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore TG Therapeutics‘s full profile, request access.

Request a free trial

TG Therapeutics Acquisitions (1)

TG Therapeutics’s most recent deal was a Merger/Acquisition with Manhattan Pharmaceuticals. The deal was made on 12-Mar-2010.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Manhattan Pharmaceuticals 12-Mar-2010 Merger/Acquisition Pharmaceuticals
To view TG Therapeutics’s complete acquisitions history, request access »

TG Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.18 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view TG Therapeutics’s complete esg history, request access »

TG Therapeutics FAQs

  • When was TG Therapeutics founded?

    TG Therapeutics was founded in 1993.

  • Where is TG Therapeutics headquartered?

    TG Therapeutics is headquartered in Morrisville, NC.

  • What is the size of TG Therapeutics?

    TG Therapeutics has 399 total employees.

  • What industry is TG Therapeutics in?

    TG Therapeutics’s primary industry is Pharmaceuticals.

  • Is TG Therapeutics a private or public company?

    TG Therapeutics is a Public company.

  • What is TG Therapeutics’s stock symbol?

    The ticker symbol for TG Therapeutics is TGTX.

  • What is the current stock price of TG Therapeutics?

    As of 20-Nov-2026 the stock price of TG Therapeutics is $63.34.

  • What is the current market cap of TG Therapeutics?

    The current market capitalization of TG Therapeutics is $9.6B.

  • What is TG Therapeutics’s current revenue?

    The trailing twelve month revenue for TG Therapeutics is $898M.

  • Who are TG Therapeutics’s competitors?

    Pfizer (Vienna), Pfizer Pakistan, Aytu Biopharma, Gesynta Pharma, and Gilead are some of the 17 competitors of TG Therapeutics.

  • What is TG Therapeutics’s annual earnings per share (EPS)?

    TG Therapeutics’s EPS for 12 months was $0.74.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process